Biotech Values

[DewDiligence]

So how about some arrangement where MNTA agrees to fund a portion of the costs of Phase-3 trials (say 25%) with the partner taking on the rest and the two parties pro-rating the split of any potential revenues accordingly.

This is likely the kind of deal that’s being discussed. I think 25% is close to the upper limit of what MNTA is willing to fund.

M118 needs to complete one or more phase-2b studies before embarking on phase-3, so what we’re talking about is the cumulative development cost for phase-2b and phase-3.